Yi Cao

机构：Hebei Medical University, Ministry of Education of the People's Republic of China, North China University of Science and Technology, Nanchang University, Sun Yat-sen University, Hunan Normal University, Chinese University of Hong Kong, Fudan University, Sixth Affiliated Hospital of Sun Yat-sen University, First Affiliated Hospital of Jiangxi Medical College, Xi'an Honghui Hospital, Affiliated Hospital of Hangzhou Normal University, Second People Hospital of Hunan, 302 Military Hospital of China, The Military General Hospital of Beijing PLA, Obstetrics and Gynecology Hospital of Fudan University, Sun Yat-sen University Cancer Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University · ORCID：0000-0002-8262-5236

发表论文 117 篇 · 总被引 3039 次 · h-index 31

代表论文

• Single-cell transcriptomic profiling uncovers cellular complexity and microenvironment in gastric tumorigenesis associated with Helicobacter pylori (2024 · Journal of Advanced Research · 被引 38)
• Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial (2023 · BMC Medicine · 被引 15)
• Melanoma-associated fibroblasts in tumor-promotion flammation and antitumor immunity: novel mechanisms and potential immunotherapeutic strategies (2024 · Human Molecular Genetics · 被引 13)
• A machine learning model for predicting the risk of diabetic nephropathy in individuals with type 2 diabetes mellitus (2025 · Frontiers in Endocrinology · 被引 6)
• Nimotuzumab combined with docetaxel and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: a multicenter, phase 2 trial (2025 · BMC Medicine · 被引 6)
• Chidamide, a Histone Deacetylase Inhibitor, Combined With R‐ GemOx in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma ( TRUST ): A Multicenter, Single‐Arm, Phase 2 Trial (2025 · Cancer Medicine · 被引 6)